drugset / Trial / NCT06450210
Safety for Home Administration of Microdose Psilocybin Use
RandomizedSequentialSingle-blindOther
Summary
The goal of this laboratory study is to establish whether and which microdoses of psilocybin are safe to administer at home to healthy participants. Eligible participants will be given ascending doses of psilocybin trihydrate and a single, interspersed, randomized placebo on separate days in double-blind fashion. The participants will be asked to complete questionnaires and undergo safety assessments.
Timeline
- Start
- 2024-12-06
- Primary completion
- 2026-07
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | 1.2 mg | Oral |
| Subject | Psilocybin | Other / unclassified | 2 mg | Oral |
| Subject | Psilocybin | Other / unclassified | 3 mg | Oral |
| Subject | Psilocybin | Other / unclassified | 4.2 mg | Oral |
Indications
No indication recorded.